{"filing":{"accession_number":"0001477932-26-006396","cik":"0001474167","ticker":"COSM","company_name":"Cosmos Health Inc.","form":"8-K","filing_date":"2026-10-22","report_date":"2026-10-19","primary_document":"cosm_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1474167/000147793226006396/cosm_8k.htm"},"events":[{"id":37133,"run_id":34233,"accession_number":"0001477932-26-006396","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.94,"summary":"Cosmos Health disclosed preliminary Q4 2026 U.S. revenue of approximately $15 million with gross profit of $10.5 million, nine-month 2026 revenue of $54.3 million (up 19%), and full-year 2026 revenue guidance exceeding $90 million (up ~38%), via press release and CEO letter.","company_name":"Cosmos Health Inc.","ticker":"COSM","filing_date":"2026-10-22","form":"8-K","submitted_at":null,"items":[{"id":41739,"accession_number":"0001477932-26-006396","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses preliminary financial results for Q4 2026 via a press release issued October 19, 2026, announcing expected U.S. revenue of approximately $15 million with gross profit of $10.5 million, along with subscription and order metrics. This is a classic earnings release disclosure under Item 2.02, attached as Exhibit 99.1 and incorporated by reference. The supplemental CEO letter (Exhibit 99.2) reinforces the earnings update with nine-month 2026 revenue of $54.3 million and full-year guidance exceeding $90 million.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-22T15:51:40.514728+00:00","company_name":"","ticker":null,"filing_date":""},{"id":41740,"accession_number":"0001477932-26-006396","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The filing discloses preliminary Q4 2026 U.S. revenue guidance of approximately $15 million with $10.5 million gross profit, and reaffirms full-year 2026 revenue expected to surpass $90 million (up ~38%), along with preliminary nine-month 2026 revenue of $54.3 million (up 19%). The CEO's letter and press release (Exhibits 99.1 and 99.2) provide detailed financial projections and business updates that constitute a material earnings/business update disclosure, even though framed as forward-looking guidance rather than historical results.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-22T15:51:40.514728+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":41739,"accession_number":"0001477932-26-006396","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses preliminary financial results for Q4 2026 via a press release issued October 19, 2026, announcing expected U.S. revenue of approximately $15 million with gross profit of $10.5 million, along with subscription and order metrics. This is a classic earnings release disclosure under Item 2.02, attached as Exhibit 99.1 and incorporated by reference. The supplemental CEO letter (Exhibit 99.2) reinforces the earnings update with nine-month 2026 revenue of $54.3 million and full-year guidance exceeding $90 million.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-22T15:51:40.514728+00:00","company_name":"Cosmos Health Inc.","ticker":"COSM","filing_date":"2026-10-22"},{"id":41740,"accession_number":"0001477932-26-006396","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The filing discloses preliminary Q4 2026 U.S. revenue guidance of approximately $15 million with $10.5 million gross profit, and reaffirms full-year 2026 revenue expected to surpass $90 million (up ~38%), along with preliminary nine-month 2026 revenue of $54.3 million (up 19%). The CEO's letter and press release (Exhibits 99.1 and 99.2) provide detailed financial projections and business updates that constitute a material earnings/business update disclosure, even though framed as forward-looking guidance rather than historical results.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-22T15:51:40.514728+00:00","company_name":"Cosmos Health Inc.","ticker":"COSM","filing_date":"2026-10-22"}]}